4//SEC Filing
Mazur Marc 4
Accession 0001628280-19-015073
CIK 0000357097other
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 4:09 PM ET
Size
25.8 KB
Accession
0001628280-19-015073
Insider Transaction Report
Form 4
Mazur Marc
Director
Transactions
- Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−6,000→ 0 totalExercise: $16.55Exp: 2027-06-22→ Common Stock (6,000 underlying) - Disposition to Issuer
Common Stock
2019-12-13$3.00/sh−600$1,800→ 0 total - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−534→ 0 totalExercise: $390.00Exp: 2020-04-01→ Common Stock (534 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−534→ 0 totalExercise: $232.50Exp: 2021-01-14→ Common Stock (534 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−534→ 0 totalExercise: $52.50Exp: 2023-02-21→ Common Stock (534 underlying) - Disposition to Issuer
Options to purchase common stock
2019-12-13−1,200→ 0 totalExercise: $62.10Exp: 2024-06-20→ Common Stock (1,200 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−6,000→ 0 totalExercise: $2.36Exp: 2028-06-19→ Common Stock (6,000 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,600→ 0 totalExercise: $82.35Exp: 2023-07-19→ Common Stock (1,600 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−2,400→ 0 totalExercise: $81.60Exp: 2025-06-24→ Common Stock (2,400 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−2,400→ 0 totalExercise: $14.25Exp: 2026-06-22→ Common Stock (2,400 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−12,000→ 0 totalExercise: $1.94Exp: 2029-06-12→ Common Stock (12,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
- [F2]Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.
Documents
Issuer
Fibrocell Science, Inc.
CIK 0000357097
Entity typeother
Related Parties
1- filerCIK 0001361226
Filing Metadata
- Form type
- 4
- Filed
- Dec 12, 7:00 PM ET
- Accepted
- Dec 13, 4:09 PM ET
- Size
- 25.8 KB